Abstract
Study Objectives To assess for associations between sleeping more than or less than recommended by the National Sleep Foundation (NSF), and self-reported insomnia, with brain structure.
Methods Data from the UK Biobank cohort were analysed (N between 9K and 32K, dependent on availability, aged 44 to 82 years). Sleep measures included self-reported adherence to NSF guidelines on sleep duration (sleeping between 7 and 9 hours per night), and self-reported difficulty falling or staying asleep (insomnia). Brain structural measures included global and regional cortical or subcortical morphometry (thickness, surface area, volume), global and tract-related white matter microstructure, brain age gap (difference between chronological age and age estimated from brain scan), and total volume of white matter lesions.
Results Longer-than-recommended sleep duration was associated with lower overall grey and white matter volumes, lower global and regional cortical thickness and volume measures, higher brain age gap, higher volume of white matter lesions, higher mean diffusivity globally and in thalamic and association fibers, and lower volume of the hippocampus. Shorter-than-recommended sleep duration was related to higher global and cerebellar white matter volumes, lower global and regional cortical surface areas, and lower fractional anisotropy in projection fibers. Self-reported insomnia was associated with higher global grey and white matter volumes, and with higher volumes of the amygdala, hippocampus and putamen.
Conclusions Sleeping longer than recommended by the NSF is associated with a wide range of differences in brain structure, potentially indicative of poorer brain health. Sleeping less than recommended is distinctly associated with lower cortical surface areas. Future studies should assess the potential mechanisms of these differences and investigate long sleep duration as a putative marker of brain health.
Competing Interest Statement
AMM previously received research grant support from Pfizer, Eli Lilly and Janssen, as well as speaker fees from Illumina. HCW previously received research grant support from Pfizer. None of these funding sources are connected to the present study. No other potential financial or non-financial conflicts of interest are reported.
Funding Statement
The current study was funded and supported through the Lister Institute of Preventive Medicine award (reference 173096) and the Wellcome-University of Edinburgh Institutional Strategic Support Fund (reference 204804/Z/16/Z). LML is supported by a Royal College of Physicians of Edinburgh John, Margaret, Alfred and Stewart Sim Fellowship and a University of Glasgow Lord Kelvin / Adam Smith (LKAS) Fellowship. MJA and XS are supported by the Wellcome Trust (grant reference 220857/Z/20/Z). The research was conducted using the UK Biobank resource, with application number 4844. Provision of access to the UK Biobank was supported by the Wellcome Trust Strategic Award "Stratifying Resilience and Depression Longitudinally" (STRADL) (reference 104036/Z/14/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank received ethical approval from the North West Multi-centre Research Ethics Committee in the UK (reference 11/NW/0382), and the current study received approval from the UK Biobank Access Committee (application #4844). All participants gave written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
1) Added Table 1 with demographic and clinical characteristics of one representative studied sample (p. 31); 2) Added details of brain-predicted age computation methods within the main text (p. 6-7); 3) Moved paragraph outlining the differences between sleep-related participant groups in terms of clinical characteristics from supplementary document to the main text (p. 8); 4) Added reference to Benjamini, Heller & Yekutieli (2009) for the applied FDR correction procedure (p. 8); 5) Added discussion of the complementary UK Biobank study reported in Schiel et al. (2023) Brain Communications (p. 18); 6) Added mention of additional correction for psychotropic medication use as a direction for future work (p. 19); 7) Added details of the rationale for the selection of cortical and subcortical morphometric measures for the study (p. 5 in the supplementary document); 8) Added details of the rationale for grouping the outcome (brain measure) variables into sets for statistical correction (p. 10-11 in the supplementary document).
Data Availability Statement
The current study used data from the UK Biobank resource, which is available for health-related research upon registration and application through the UK Biobank Access Management System (https://www.ukbiobank.ac.uk/register-apply/).
